CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas: Diagnostic and Therapeutic Implications

CD137 (also known as 4-1BB and TNFRSF9) is a member of the tumor necrosis factor receptor superfamily. Originally identified as a costimulatory molecule expressed by activated T cells and NK cells, CD137 is also expressed by follicular dendritic cells, monocytes, mast cells, granulocytes, and endoth...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of pathology Vol. 181; no. 3; pp. 795 - 803
Main Authors ANDERSON, Matthew W, SHUCHUN ZHAO, SPECTOR, Nelson, MOLINA-KIRSCH, Hernan F, WARNKE, Roger A, LEVY, Ronald, NATKUNAM, Yasodha, FREUD, Aharon G, CZERWINSKI, Debra K, KOHRT, Holbrook, ALIZADEH, Ash A, HOUOT, Roch, AZAMBUJA, Denize, BIASOLI, Irene, MORAIS, José Carlos
Format Journal Article
LanguageEnglish
Published Bethesda, MD American Society for Investigative Pathology 01.09.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:CD137 (also known as 4-1BB and TNFRSF9) is a member of the tumor necrosis factor receptor superfamily. Originally identified as a costimulatory molecule expressed by activated T cells and NK cells, CD137 is also expressed by follicular dendritic cells, monocytes, mast cells, granulocytes, and endothelial cells. Anti-CD137 immunotherapy has recently shown promise as a treatment for solid tumors and lymphoid malignancies in preclinical models. We defined the expression of CD137 protein in both normal and neoplastic hematolymphoid tissue. CD137 protein is expressed by follicular dendritic cells in the germinal center and scattered paracortical T cells, but not by normal germinal-center B cells, bone marrow progenitor cells, or maturing thymocytes. CD137 protein is expressed by a select group of hematolymphoid tumors, including classical Hodgkin lymphoma, T-cell and NK/T-cell lymphomas, and follicular dendritic cells neoplasms. CD137 is a novel diagnostic marker of these tumors and suggests a possible target for tumor-directed antibody therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9440
1525-2191
DOI:10.1016/j.ajpath.2012.05.015